Uterine Fibroids Clinical Trial
Official title:
For Research Purpose the Clinical Test of the Magnetic Resonance Imaging Guided Focused Ultrasound Ablation System on Uterine Fibroids
The objectives of this program are to verify the safety and effectiveness of the MRgHIFU system developed by the division of Medical Engineering of National Health Research Institutes (NHRI)
Between 25 % - 50 % of women of childbearing age have uterine fibroids. Also, 25% of women
with fibroids suffer from the metrorrhagia, menorrhagia, dysmenorrheal or pelvic compression
so that they don't have a good quality of life. The worse case is the fertility of patients
with fibroids is hindered. The current clinical treatment is medication or surgery.
Medication can only suppress the symptom temporarily when the hysterectomy method of
removing part or all of uterus can cure the patient completely. However, the hysterectomy is
an invasive operation and the women with fibroids who plan to have a baby don't accept this
kind of treatment.
Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the
noninvasive treatment of uterine fibroids has been developed and was approved by the US Food
and Drug Administration (FDA) in 2004. The ultrasound waves emitted by the ultrasonic probe
propagate through the skin, fat, muscle, soft tissues and converge on fibroids at focus.
High energy/intensity at focus causes the thermal necrosis of the fibroid tissue in several
seconds. The whole process of HIFU ablation of fibroids is monitored and guided by MR
thermometery. The advantage of MR-HIFU modality includes no incision, outpatient treatment
and few side effects.
The objectives of this program are to verify the safety and effectiveness of the MRgHIFU
system developed by the division of Medical Engineering of National Health Research
Institutes (NHRI), to achieve the clinical trial at the Chang-Gung Memorial Hospitals of
Linkou and to commercialize the self-developed MRgHIFU system. The mission is to conduct the
first-stage clinical test for 10 women with symptomatic uterine fibroids and to make two
sets of HIFU system. Meanwhile, the impact of quality of life and satisfaction with
treatment of the patients diagnosed with symptomatic uterine fibroids will be analyzed.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01441635 -
Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine Fibroids
|
Phase 2 | |
| Completed |
NCT00958334 -
Extension Study of Proellex in Women Who Have Previously Completed Study ZPU 003
|
Phase 2 | |
| Withdrawn |
NCT04567589 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Healthcare Professionals in Canada
|
||
| Recruiting |
NCT05078307 -
Evaluation of a Hysteroscopic Method With Vaporization in the Hysteroscopic Treatment of Submucosal Uterine Fibroids
|
N/A | |
| Completed |
NCT01631903 -
Extension of Study ZPV-200
|
Phase 2 | |
| Completed |
NCT01739621 -
Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200
|
Phase 2 | |
| Withdrawn |
NCT00768742 -
Safety and Effectiveness Study of RF Ablation of Uterine Fibroids to Reduce Menstrual Bleeding: the Fibroid Ablation Study
|
N/A | |
| Completed |
NCT00152256 -
A Study to Evaluate of the Safety and Effectiveness of Asoprisnil in Treating Women With Uterine Fibroids
|
Phase 3 | |
| Not yet recruiting |
NCT03586947 -
Association Between Vitamin D and the Risk of Uterine Fibroids
|
N/A | |
| Completed |
NCT02925494 -
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
Phase 3 | |
| Not yet recruiting |
NCT06055114 -
Study on Vaginal Microecology and Cervical Local Immune Function in Patients With Uterine Fibroids of Childbearing Age
|
||
| Terminated |
NCT05026502 -
A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
|
||
| Withdrawn |
NCT04567095 -
A Study to Evaluate Awareness and Knowledge of the Fibristal Additional Risk Minimization Measures Among Patients in Canada
|
||
| Withdrawn |
NCT03699176 -
Assessment of Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
|
Phase 3 | |
| Not yet recruiting |
NCT02884960 -
Safety and Efficacy of Embozene Microspheres for Uterine Fibroid Embolization
|
N/A | |
| Completed |
NCT02472184 -
Optimal Order of Concurrent Office Hysteroscopy and Endometrial Biopsy
|
N/A | |
| Completed |
NCT01452659 -
Efficacy and Safety of TAK-385 in the Treatment of Uterine Fibroids
|
Phase 2 | |
| Terminated |
NCT01555073 -
Preemptive Analgesia Following Uterine Artery Embolization
|
Phase 4 | |
| Completed |
NCT01229826 -
Magnetic Resonance Elastography (MRE) of Uterine Fibroids
|
N/A | |
| Terminated |
NCT00737282 -
Multicenter Study Evaluating the Safety of Proellex® in Premenopausal Women With Uterine Fibroids
|
Phase 3 |